glp-1 explanation Understanding receptor agonists and their impact on drug discovery Frontiers | Mechanisms of action
Description
2022;8:e164
Tirzepatide, a dual GIP/GLP-1 agonist, showed up to 20.9% average weight loss in SURMOUNT-1 at 72 weeks
The gains compound when paired with regular movement and decent sleep
10.1016/j.mito.2008.02.001 5 ArandaA.PascualA
Effect of weight reduction on insulin sensitivity, sex hormone-binding globulin, sex hormones and gonadotrophins in obese children
2 The relationship between obesity and MASLD is tightly intertwined
